Track your investments for FREE with Simply Wall St, the portfolio command center trusted by over 7 million individual investors worldwide.
-
If you are wondering whether Alcon stock offers fair value around its recent price, or if the risks are starting to outweigh the potential, this article walks through the key signals to help you answer that for yourself.
-
Over shorter periods the stock has been mixed, up 3.6% over the last week, but down 10.2% over the last month, 16.1% year to date, and 26.1% over the past year, which may have shifted how investors are thinking about both risk and opportunity.
-
Recent coverage has focused on Alcon in the context of broader sector sentiment and investor interest in healthcare stocks. This helps explain some of the shorter term price swings and provides useful context when you assess whether current pricing fairly reflects the business or leans too much on near term mood.
-
Alcon currently has a valuation score of 3 out of 6. Next you will see how different valuation methods line up with that score, before finishing with a way to judge value that goes beyond any single model.
Find out why Alcon's -26.1% return over the last year is lagging behind its peers.
Approach 1: Alcon Discounted Cash Flow (DCF) Analysis
A Discounted Cash Flow model estimates what a stock could be worth by projecting the company's future cash flows and then discounting them back to today's value using an appropriate rate. It is essentially asking what those future dollars are worth in today's terms.
For Alcon, the model used is a 2 Stage Free Cash Flow to Equity approach, built on cash flow projections rather than earnings. The latest twelve month free cash flow is about US$1.51b. Analyst inputs and extrapolations suggest free cash flow of about US$2.39b in 2030, with intermediate yearly projections between 2026 and 2035 that Simply Wall St extrapolates beyond the period where analysts typically provide estimates.
Discounting these projected cash flows back to today produces an estimated intrinsic value of US$90.35 per share. Compared with the current share price, the DCF output points to an implied discount of 41.0%, indicating the stock screens as undervalued on this model alone.
Result: UNDERVALUED
Our Discounted Cash Flow (DCF) analysis suggests Alcon is undervalued by 41.0%. Track this in your watchlist or portfolio , or discover 213 more high quality undervalued stocks .
Approach 2: Alcon Price vs Earnings
The P/E ratio is a common way to look at valuation for profitable companies because it links what you pay for each share with the earnings that support that share. It gives you a quick sense of how many years of current earnings the market is willing to pay for.
What counts as a "normal" P/E depends on how the market sees a company's growth prospects and risk profile. Higher expected earnings growth or lower perceived risk can support a higher multiple, while slower growth or higher risk usually calls for a lower one.
Alcon currently trades on a P/E of about 40.4x. That sits above the Medical Equipment industry average of roughly 25.4x and also above the broader peer group average of about 25.2x. To add more context, Simply Wall St calculates a proprietary "Fair Ratio" for Alcon of 34.9x. This is the P/E that might be expected given factors such as its earnings growth profile, profit margins, market cap, risks and industry.
This Fair Ratio can be more useful than a simple industry or peer comparison because it adjusts for those company specific traits rather than assuming all stocks deserve the same multiple. Comparing Alcon's current P/E of 40.4x with the Fair Ratio of 34.9x suggests the stock screens as overvalued on this measure.
Result: OVERVALUED
P/E ratios tell one story, but what if the real opportunity lies elsewhere? Start investing in legacies, not executives. Discover our 101 top founder-led companies .
Upgrade Your Decision Making: Choose your Alcon Narrative
Earlier it was mentioned that there is an even better way to understand valuation. Meet Narratives, which let you attach a clear story about Alcon to the numbers by spelling out what you think happens to its future revenue, earnings and margins, then linking that forecast to a Fair Value that you can compare with today's price.
On Simply Wall St, Narratives sit inside the Community page and are designed so any investor can quickly see how a company's story feeds into a set of assumptions and a Fair Value. You can then use the gap between Fair Value and price to help decide whether the stock looks expensive or cheap relative to that story, without needing to build a full model.
Because Narratives update as new information such as product launches, buybacks, impairments or legal rulings arrives, you always see how fresh assumptions feed into value. With Alcon you can already see this in action, with some investors building very optimistic Narratives that point to Fair Value around CHF 88.89 and others using more cautious Narratives closer to CHF 60.81, giving you a clear range of stories to compare with your own view.
Do you think there's more to the story for Alcon? Head over to our Community to see what others are saying!
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include ALC.SW .
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
